Effect of recombinant human IFNγ in the treatment of chronic pulmonary complications due to sulfur mustard intoxication

Journal of Immunotoxicology

Volumn 11, Issue 1, 2014, Pages 72-77

  Panahi, Yunes ^a   Ghanei, Mostafa ^a   Vahedi, Ensieh ^a   Ghazvini, Ali ^a   Parvin, Shahram ^a   Madanchi, Nima ^b   Bagheri, Mahsa ^c   Sahebkar, Amirhossein ^d  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti oxidant; Immunomodulation; Interferon ; Mustard gas; Quality of life

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CATALASE; GAMMA IMMUNEX; GAMMA INTERFERON; GELATINASE B; GLUTATHIONE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MALONALDEHYDE; MUSTARD GAS; RECOMBINANT GAMMA INTERFERON; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE;

ADULT; ARTICLE; CHRONIC LUNG DISEASE; CLINICAL ARTICLE; COUGHING; DISEASE SEVERITY; DRUG INDUCED HEADACHE; DYSPNEA; FLU LIKE SYNDROME; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEMOPTYSIS; HUMAN; MIDDLE AGED; NAUSEA AND VOMITING; OXIDATIVE STRESS; PRIORITY JOURNAL; QUALITY OF LIFE; SPUTUM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; BLOOD; CHRONIC DISEASE; COMPLICATION; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; INTOXICATION; LUNG DISEASES; LUNG FUNCTION TEST; PROCEDURES; QUESTIONNAIRE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; CALCITONIN GENE-RELATED PEPTIDE; CHRONIC DISEASE; CYTOKINES; HUMANS; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; LUNG DISEASES; MUSTARD GAS; OXIDATIVE STRESS; POISONING; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; SURVEYS AND QUESTIONNAIRES;

EID: 84896516346     PISSN: 1547691X     EISSN: None     Source Type: Journal    
DOI: 10.3109/1547691X.2013.797525     Document Type: Article

References (53)

1. Akerboom, T. P., and Sies, H. 1981. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Meth. Enzymol. 77:373-382.
2. Anonymous. 1986. Reports of specialists appointed by the Secretary General to investigate allegations by the Islamic Republic of Iran concerning the use of chemical weapons. USA: New York Security Council of United Nations document, pp. 16433.
3. Calvet, J. H., Planus, E., Rouet, P., et al. 1999. Matrix metalloproteinase gelatinases in sulfur mustard-induced acute airway injury in guinea pigs. Am. J. Physiol. 276:L754-762.
4. Chakrabarti, S., and Patel, K. D. 2005. Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology. Exp. Lung Res. 31:599-621.
5. Chance, B., and Maehly, A. C. 1995. Assay of catalase and peroxidase. In: Methods in Enzymology (Colowick, S. P., and Kaplan, N. D., Eds.). New York: Academic Press, pp. 764-791.
6. Cheresh, P., Kim, S. J., Tulasiram, S., and Kamp, D. W. 2013. Oxidative stress and pulmonary fibrosis. Biochim. Biophys. Acta. 1832:1028-1040.
7. Corbel, M., Belleguic, C., Boichot, E., and Lagente, V. 2002. Involvement of gelatinases (MMP-2 and MMP-9) in development of airway inflammation and pulmonary fibrosis. Cell Biol. Toxicol. 18:51-61.
8. de Vries, J. E. 1995. Immunosuppressive and anti-inflammatory properties of IL-10. Ann. Med. 27:537-541.
9. Du Bois, R. M. 1999. IFNg-1b for treatment of idiopathic pulmonary fibrosis. New Engl. J. Med. 341:1302-1324.
10. Emad, A., and Emad, Y. 2007. CD4/CD8 ratio and cytokine levels of the BAL fluid in patients with bronchiectasis caused by sulfur mustard gas inhalation. J. Inflamm. (Lond.) 4:2.
11. Emad, A., and Rezaian, G. R. 1997. The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: Analysis of 197 cases. Chest 112:734-738.
12. Geirsson, A., Singh, M., Ali, R., et al. 2012. Modulation of TGFb signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers. Circulation 126:S189-S197.
13. Ghabili, K., Agutter, P. S., Ghanei, M., et al. 2011. Sulfur mustard toxicity: History, chemistry, pharmacokinetics, and pharmacodynamics. Crit. Rev. Toxicol. 41:384-403.
14. Ghanei, M., Panahi, Y., Mojtahedzadeh, M., et al. 2006. Effect of IFNg on lung function of mustard gas exposed patients, after 15 years. Pulm. Pharmacol. Ther. 19:148-153.
15. Grande, J. P., Melder, D. C., and Zinsmeister, A. R. 1997. Modulation of collagen gene expression by cytokines: Stimulatory effect of TGFb1, with divergent effects of EGF and TNFa on collagen Type I and collagen Type IV. J. Lab. Clin. Med. 130:476-486.
16. Gruner, S., Liebenthal, C., Heusser, C., et al. 1991. The influence of IFNg and IL-4 on IgE production in B-lymphocytes of patients with atopic dermatitis. Possible criterion for selection of patients for interferon therapy. Acta Derm. Venereol. 71:484-487.
17. Gurujeyalakshmi, G., and Giri, S. N. 1995. Molecular mechanisms of anti-fibrotic effect of IFNg in bleomycin-mouse model of lung fibrosis: Down-regulation of TGF and procollagen I and III gene expression. Exp. Lung Res. 21:791-808.
18. Han, S., Espinoza, L. A., Liao, H., et al. 2004. Protection by anti-oxidants against toxicity and apoptosis induced by the sulphur mustard analog 2-chloro-ethylethyl sulphide (CEES) in Jurkat T-cells and normal human lymphocytes. Br. J. Pharmacol. 141:795-802.
19. Hengge, U. R., Ruzicka, T., Schwartz, R. A., and Cork, M. J. 2006. Adverse effects of topical glucocorticosteroids. J. Am. Acad. Dermatol. 54:1-15.
20. Husain, K., Dube, S. N., Sugendran, K., et al. 1996. Effect of topicallyapplied sulphur mustard on anti-oxidant enzymes in blood cells and body tissues of rats. J. Appl. Toxicol. 16:245-248.
21. Jafari, M. 2007. Dose-and time-dependent effects of sulfur mustard on anti-oxidant system in liver and brain of rat. Toxicology 231:30-39.
22. Jones, P. W., Harding, G., Berry, P., et al. 2009. Development and first validation of the COPD Assessment Test. Eur. Respir. J. 34:648-654.
23. Keane, M. P. 2008. Role of chemokines and cytokines in lung fibrosis. Eur. Respir. Rev. 17:151-156.
24. Khateri, S., Ghanei, M., Keshavarz, S., et al. 2003. Incidence of lung, eye, and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. J. Occup. Environ. Med. 45:1136-1143.
25. Korkmaz, A., Oter, S., Sadir, S., et al. 2005. Peroxynitrite may be involved in bladder damage caused by cyclophosphamide in rats. J. Urol. 173:1793-1796.
26. Lagente, V., Manoury, B., Nénan, S., et al. 2005. Role of matrix metalloproteinases in the development of airway inflammation and remodeling. Braz. J. Med. Biol. Res. 38:1521-1530.
27. Li, X. M., and Zhai, L. D. 2008. Influence of IFNg in combination with methylprednisolone on proliferation of human embryonic lung fibroblast. J. Clin. Rehab. Tissue Eng. Res. 12:2829-2833.
28. Losa Garcia, J. E., Rodriguez, F. M., Martin de Cabo, M. R., et al. 1999. Evaluation of inflammatory cytokine secretion by human alveolar macrophages. Med. Inflamm. 8:43-51.
29. Louis, S. M., Johnstone, D., Russell, N. J., et al. 1989. Antibodies to calcitonin-gene related peptide reduce inflammation induced by topical mustard oil but not that due to carrageenan in the rat. Neurosci. Lett. 102:257-260.
30. Malaviya, R., Sunil, V. R., Cervelli, J., et al. 2010. Inflammatory effects of inhaled sulfur mustard in rat lung. Toxicol. Appl. Pharmacol. 248:89-99.
31. Meguro, M., Barley, E. A., Spencer, S., and Jones, P. W. 2007. Development and validation of an improved, COPD-Specific Version of the St. George Respiratory Questionnaire. Chest 132:456-463.
32. Naghii, M. R. 2002. Sulfur mustard intoxication, oxidative stress, and anti-oxidants. Mil. Med. 167:573-575.
33. Panahi, Y., Davoudi, S. M., Sadr, S. B., et al. 2008. Impact of pruritus on quality of life in sulfur mustard-exposed Iranian veterans. Int. J. Dermatol. 47:557-561.
34. Panahi, Y., Davoudi, S. M., Sahebkar, A., et al. 2012a. Efficacy of aloe vera/olive oil cream vs. betamethasone cream for chronic skin lesions following sulfur mustard exposure: A randomized double-blind clinical trial. Cutan. Ocul. Toxicol. 31:95-103.
35. Panahi, Y., Sahebkar, A., Amiri, M., et al. 2012b. Improvement of sulphur mustard-induced chronic pruritus, quality of life and anti-oxidant status by curcumin: Results of a randomised, double-blind, placebocontrolled trial. Br. J. Nutr. 108:1272-1279.
36. Panahi, Y., Sahebkar, A., Davoudi, S. M., et al. 2012c. Efficacy and safety of immunotherapy with interferon-g in the management of chronic sulfur mustard-induced cutaneous complications: Comparison with topical betamethasone 1. ScientificWorldJournal 2012;285274.
37. Panahi, Y., Sahebkar, A., Parvin, S., and Saadat, A. 2012d. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann. Clin. Biochem. 49:580-588.
38. Panahi, Y., Sarayani, A., Beiraghdar, F., et al. 2012e. Management of sulfur mustard-induced chronic pruritus: A review of clinical trials. Cutan. Ocul. Toxicol. 31:220-225.
39. Pohanka, M., and Stetina, R. 2009. Shift of oxidants and anti-oxidants levels in rats as a reaction to exposure to sulfur mustard. J. Appl. Toxicol. 29:643-647.
40. Pourfarzam, S., Ghazanfari, T., Yaraee, R., et al. 2009. Serum levels of IL-8 and IL-6 in the long-term pulmonary complications induced by sulfur mustard: Sardasht-Iran Cohort Study. Int. Immunopharmacol. 9:1482-1488.
41. Prior, C., and Haslam, P. L. 1992. In vivo levels and in vitro production of IFNg in fibrosing interstitial lung diseases. Clin. Exp. Immunol. 88:28-287.
42. Raghu, G., Masta, S., Meyers, D., and Narayanan, A. S. 1989. Collagen synthesis by normal and fibrotic human lung fibroblasts and the effect of TGFb. Am. Rev. Respir. Dis. 140:95-100.
43. Rahman, I. 2005. The role of oxidative stress in the pathogenesis of COPD: Implications for therapy. Treat. Respir. Med. 4:175-200.
44. Sahebkar, A. 2012. Baicalin as a potentially promising drug for the management of sulfur mustard induced cutaneous complications: A review of molecular mechanisms. Cutan. Ocul. Toxicol. 31:226-234.
45. Sato, A., Tsuji, K., Yamamura, M., et al. 1998. Increased Type 2 cytokine expression by both CD4\+ CD45RO\+ T-cells and CD8\+ CD45RO\+ Tcells in blood circulation is associated with high serum IgE but not with atopic dermatitis. J. Invest. Dermatol. 111:1079-1084.
46. Thannickal, V. J., Lee, D. Y., White, E. S., et al. 2003. Myofibroblast differentiation by TGFb1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J. Biol. Chem. 278:12384-12389.
47. Thomas, S. R., and Stocker, R. 1999. Anti-oxidant activities and redox regulation of IFNg-induced tryptophan metabolism in human monocytes and macrophages. Adv. Exp. Med. Biol. 467:541-552.
48. Tomasek, J. J., Gabbiani, G., Hinz, B., et al. 2002. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell. Biol. 3:349-363.
49. Tzouvelekis, A., Bouros, E., and Bouros, D. 2010. The immunology of pulmonary fibrosis: The role of TH1/TH2/TH17/Treg cells. Pneumon 23:13-20.
50. Uchiyama, M., and Mihara, M. 1978. Determination of malondialdehyde precursor in tissue by thiobarbituric acid test. Anal. Biochem. 34: 271-278.
51. Wen, F. Q., Liu, X., Kobayashi, T., et al. 2004. IFNg inhibits TGFb production in human airway epithelial cells by targeting Smads. Am. J. Respir. Cell Mol. Biol. 30:816-822.
52. Yaraee, R., Ghazanfari, T., Faghihzadeh, S., et al. 2009. Alterations in the serum levels of soluble L, P, and E-selectin 20 years after sulfur mustard exposure: Sardasht-Iran Cohort Study. Int. Immunopharmacol. 9:1477-1481.
53. Ziesche, R., and Block, L. H. 2000. Mechanisms of anti-fibrotic action of IFNg-1b in pulmonary fibrosis. Wien Klin. Wochenschr. 112:785-790.